» Articles » PMID: 18984734

Site-specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2008 Nov 6
PMID 18984734
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: O-linked N-acetylglucosamine (O-GlcNAc) is upregulated in diabetic tissues and plays a role in insulin resistance and glucose toxicity. Here, we investigated the extent of GlcNAcylation on human erythrocyte proteins and compared site-specific GlcNAcylation on erythrocyte proteins from diabetic and normal individuals.

Research Design And Methods: GlcNAcylated erythrocyte proteins or GlcNAcylated peptides were tagged and selectively enriched by a chemoenzymatic approach and identified by mass spectrometry. The enrichment approach was combined with solid-phase chemical derivatization and isotopic labeling to detect O-GlcNAc modification sites and to compare site-specific O-GlcNAc occupancy levels between normal and diabetic erythrocyte proteins.

Results: The enzymes that catalyze the cycling (addition and removal) of O-GlcNAc were detected in human erythrocytes. Twenty-five GlcNAcylated erythrocyte proteins were identified. Protein expression levels were compared between diabetic and normal erythrocytes. Thirty-five O-GlcNAc sites were reproducibly identified, and their site-specific O-GlcNAc occupancy ratios were calculated.

Conclusions: GlcNAcylation is differentially regulated at individual sites on erythrocyte proteins in response to glycemic status. These data suggest not only that site-specific O-GlcNAc levels reflect the glycemic status of an individual but also that O-GlcNAc site occupancy on erythrocyte proteins may be eventually useful as a diagnostic tool for the early detection of diabetes.

Citing Articles

Interplay Between Metabolic Pathways and Increased Oxidative Stress in Human Red Blood Cells.

Spinelli S, Marino A, Morabito R, Remigante A Cells. 2024; 13(23).

PMID: 39682773 PMC: 11640724. DOI: 10.3390/cells13232026.


The post-translational modification O-GlcNAc is a sensor and regulator of metabolism.

Morales M, Pratt M Open Biol. 2024; 14(10):240209.

PMID: 39474868 PMC: 11523104. DOI: 10.1098/rsob.240209.


Mass Spectrometry-Based Proteomics for the Masses: Peptide and Protein Identification in the Hunt Laboratory During the 2000's.

Chapman J Mol Cell Proteomics. 2024; 23(12):100866.

PMID: 39442692 PMC: 11696785. DOI: 10.1016/j.mcpro.2024.100866.


Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.

Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.

PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.


Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures.

Hu J, Xia W, Zeng S, Lim Y, Tao Y, Sun Y Nat Commun. 2024; 15(1):2677.

PMID: 38538591 PMC: 10973503. DOI: 10.1038/s41467-024-46898-1.


References
1.
Vosseller K, Wells L, Lane M, Hart G . Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 2002; 99(8):5313-8. PMC: 122766. DOI: 10.1073/pnas.072072399. View

2.
Ramakrishnan B, Qasba P . Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. J Biol Chem. 2002; 277(23):20833-9. DOI: 10.1074/jbc.M111183200. View

3.
Pasini E, Kirkegaard M, Mortensen P, Lutz H, Thomas A, Mann M . In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood. 2006; 108(3):791-801. DOI: 10.1182/blood-2005-11-007799. View

4.
. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979; 28(12):1039-57. DOI: 10.2337/diab.28.12.1039. View

5.
Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L . Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest. 1997; 99(9):2173-82. PMC: 508047. DOI: 10.1172/JCI119390. View